Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody.
Yuki KatohTomonori YaguchiAkiko KuboTakashi IwataKenji MoriiDaiki KatoShigeki OhtaRyosuke SatomiYasuhiro YamamotoYoshitaka OyamadaKota OuchiShin TakahashiChikashi IshiokaRyo MatobaMakoto SuematsuYutaka KawakamiPublished in: Journal for immunotherapy of cancer (2022)
SCD1 expressed in cancer cells and immune cells causes immunoresistant conditions, and its inhibition augments antitumor T cells and therapeutic effects of anti-PD-1 antibody. Therefore, SCD1 is an attractive target for the development of new diagnostic and therapeutic strategies to improve current cancer immunotherapies including immune checkpoint inhibitors.